Stochastic asymmetric repartition of lytic machinery in dividing CD8+ T cells generates heterogeneous killing behavior

  1. Fanny Lafouresse  Is a corresponding author
  2. Romain Jugele
  3. Sabina Müller
  4. Marine Doineau
  5. Valérie Duplan-Eche
  6. Eric Espinosa
  7. Marie-Pierre Puissegur
  8. Sébastien Gadat
  9. Salvatore Valitutti
  1. Centre de Recherche en Cancérologie de Toulouse, France
  2. Toulouse School of Economics, UMR 5604, France
  3. Centre de Physiopathologie de Toulouse Purpan, France

Abstract

Cytotoxic immune cells are endowed with a high degree of heterogeneity in their lytic function, but how this heterogeneity is generated is still an open question. We therefore investigated if human CD8+ T cells could segregate their lytic components during telophase, using imaging flow cytometry, confocal microscopy and live cell imaging. We show that CD107a+-intracellular vesicles, perforin and granzyme B unevenly segregate in a constant fraction of telophasic cells during each division round. Mathematical modeling posits that unequal lytic molecule inheritance by daughter cells results from the random distribution of lytic granules on the two sides of the cleavage furrow. Finally, we establish that the level of lytic compartment in individual CTL dictates CTL killing capacity. Together, our results show the stochastic asymmetric distribution of effector molecules in dividing CD8+ T cells. They propose uneven mitotic repartition of pre-packaged lytic components as a mechanism generating non-hereditary functional heterogeneity in CTL.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files.

Article and author information

Author details

  1. Fanny Lafouresse

    INSERM U1037, Centre de Recherche en Cancérologie de Toulouse, Toulouse, France
    For correspondence
    fanny.lafouresse@inserm.fr
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6572-8631
  2. Romain Jugele

    INSERM U1037, Centre de Recherche en Cancérologie de Toulouse, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  3. Sabina Müller

    INSERM U1037, Centre de Recherche en Cancérologie de Toulouse, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  4. Marine Doineau

    Mathematics of decision making and statistics, Toulouse School of Economics, UMR 5604, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  5. Valérie Duplan-Eche

    INSERM, UMR1043, Centre de Physiopathologie de Toulouse Purpan, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  6. Eric Espinosa

    INSERM U1037, Centre de Recherche en Cancérologie de Toulouse, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  7. Marie-Pierre Puissegur

    INSERM U1037, Centre de Recherche en Cancérologie de Toulouse, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  8. Sébastien Gadat

    Mathematics of decision making and statistics, Toulouse School of Economics, UMR 5604, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  9. Salvatore Valitutti

    INSERM U1037, Centre de Recherche en Cancérologie de Toulouse, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.

Funding

Laboratoire d'Excellence Toulouse Cancer (ANR11-LABEX)

  • Salvatore Valitutti

Region occitanie (RCLE R14007BB,671 34 No 12052802,and RBIO R15070BB,No 14054342)

  • Salvatore Valitutti

Fondation Toulouse Cancer Santé (2014CS044)

  • Salvatore Valitutti

Ligue Contre le Cancer (équipe labellisée)

  • Salvatore Valitutti

Ligue Contre le Cancer (4th year phD)

  • Romain Jugele

Bristol-Myers Squibb (No CA184-575)

  • Salvatore Valitutti

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: Buffy coats of healthy donors were obtained through the Etablissement Français du Sang (EFS, Toulouse, France). Blood samples were collected and processed following standard ethical procedures (Helsinki 433 protocol), after obtaining written informed consent from each donor and approval by the French Ministry of the Research (transfer agreement AC-2014-2384). Approbation by the ethical department of the French Ministry of the Research for the preparation and conservation of cell lines and clones starting from healthy donor human blood samples has been obtained (authorization No DC-2018-3223).

Copyright

© 2021, Lafouresse et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,282
    views
  • 194
    downloads
  • 8
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Fanny Lafouresse
  2. Romain Jugele
  3. Sabina Müller
  4. Marine Doineau
  5. Valérie Duplan-Eche
  6. Eric Espinosa
  7. Marie-Pierre Puissegur
  8. Sébastien Gadat
  9. Salvatore Valitutti
(2021)
Stochastic asymmetric repartition of lytic machinery in dividing CD8+ T cells generates heterogeneous killing behavior
eLife 10:e62691.
https://doi.org/10.7554/eLife.62691

Share this article

https://doi.org/10.7554/eLife.62691

Further reading

    1. Cell Biology
    2. Immunology and Inflammation
    Alejandro Rosell, Agata Adelajda Krygowska ... Esther Castellano Sanchez
    Research Article

    Macrophages are crucial in the body’s inflammatory response, with tightly regulated functions for optimal immune system performance. Our study reveals that the RAS–p110α signalling pathway, known for its involvement in various biological processes and tumourigenesis, regulates two vital aspects of the inflammatory response in macrophages: the initial monocyte movement and later-stage lysosomal function. Disrupting this pathway, either in a mouse model or through drug intervention, hampers the inflammatory response, leading to delayed resolution and the development of more severe acute inflammatory reactions in live models. This discovery uncovers a previously unknown role of the p110α isoform in immune regulation within macrophages, offering insight into the complex mechanisms governing their function during inflammation and opening new avenues for modulating inflammatory responses.

    1. Immunology and Inflammation
    2. Microbiology and Infectious Disease
    Malika Hale, Kennidy K Takehara ... Marion Pepper
    Research Article

    Pseudomonas aeruginosa (PA) is an opportunistic, frequently multidrug-resistant pathogen that can cause severe infections in hospitalized patients. Antibodies against the PA virulence factor, PcrV, protect from death and disease in a variety of animal models. However, clinical trials of PcrV-binding antibody-based products have thus far failed to demonstrate benefit. Prior candidates were derivations of antibodies identified using protein-immunized animal systems and required extensive engineering to optimize binding and/or reduce immunogenicity. Of note, PA infections are common in people with cystic fibrosis (pwCF), who are generally believed to mount normal adaptive immune responses. Here, we utilized a tetramer reagent to detect and isolate PcrV-specific B cells in pwCF and, via single-cell sorting and paired-chain sequencing, identified the B cell receptor (BCR) variable region sequences that confer PcrV-specificity. We derived multiple high affinity anti-PcrV monoclonal antibodies (mAbs) from PcrV-specific B cells across three donors, including mAbs that exhibit potent anti-PA activity in a murine pneumonia model. This robust strategy for mAb discovery expands what is known about PA-specific B cells in pwCF and yields novel mAbs with potential for future clinical use.